Overview
Corporate advisory focused on investor-management trust.
Deals · 12mo
1
Links
Stage focus
Geographic focus
Sector focus
Investment portfolio
- Craif
Led · Series D · Aug 2026
Craif develops a urine analysis platform that combines proprietary biomarker detection and AI to assess disease risk, with cancer as its initial focus. Its flagship test, miSignal, is available at more than 2,500 medical institutions and 4,500 pharmacies in Japan, and the company has performed over 110,000 tests to date. Craif analyzes microRNA signals and has published more than 90 peer-reviewed papers and conference presentations, including two independent publications on early pancreatic cancer detection. The company is advancing a software-based medical device program targeting pancreatic cancer and plans a prospective clinical study in the U.S. from its San Diego laboratory. Craif opened its San Diego lab in April 2026, established a U.S. subsidiary in 2022, and is building clinical, regulatory, and commercial capabilities to support a reimbursement-driven U.S. launch.